SAS Output

03-DEC-2020 6:10

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY ADMIN CCADMIN R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac PREV   0 Y 0 Pre-Registration 621 28 17 8 2 1
            621 28 17 8 2 1
 
      1 Y 1 Blinded drug 111 17 11 6 2 0
          2 Blinded drug 36 0 0 0 0 0
          3 Blinded drug 35 0 0 0 0 0
          4 Blinded drug 114 19 10 6 1 0
            296 36 21 12 3 0
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) BREAST SXQOL 1 Y 1 Tissue for PD-L1 testing 1118 379 200 99 35 4
            1118 379 200 99 35 4
 
      2 Y 2 Observation 479 160 86 40 16 6
          3 MK-3475 (Pembrolizumab) 475 162 83 36 8 1
            954 322 169 76 24 7
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol SURV   1 Y 0 Screening 231 68 30 11 2 0
            231 68 30 11 2 0
 
      2 Y 1 Carvedilol 42 12 3 2 1 0
          2 No prophylaxis 44 13 7 1 0 0
          3 Observation 131 37 17 8 2 0
            217 62 27 11 3 0
 
S1600-Bladder,Radical Cystectomy Outcomes Nutrition SXQOL   1 Y 1 Blinded Nutrition Drink 7 2 2 2 2 2
          2 Blinded Nutrition Drink 11 1 1 1 1 1
            18 3 3 3 3 3
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG GU SXQOL 1 Y 1 TICE BCG 318 150 79 44 12 2
          2 Tokyo-172 BCG 322 154 82 47 15 5
          3 Prime + Tokyo-172 BCG 327 160 87 48 18 4
            967 464 248 139 45 11
 
S1614-HBV in Ca Pts, TAF vs SOC SXQOL   1 T 4 SOC HBV Treatment 2 2 0 0 0 0
            2 2 0 0 0 0
 
S1703-Met Breast, STM-monitoring v Usual Care CCD SXQOL 1 Y 0 Screening 194 104 62 32 7 1
            194 104 62 32 7 1
 
      2 Y 1 Control (Usual Care) 55 31 20 13 3 1
          2 Intervention (STMDDM) 56 33 19 12 2 1
            111 64 39 25 5 2
 
S1714-CIPN Risk Prediction Cohort Study, Taxanes SXQOL   1 Y 1 Observation 568 466 270 171 68 11
            568 466 270 171 68 11
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum GU SXQOL 1 Y 0 Induction SST 271 132 78 42 13 1
            271 132 78 42 13 1
 
      2 Y 1 Standard Systemic Therapy Only 91 51 22 9 2 0
          2 SST + Surgery/RT 92 52 24 12 1 0
            183 103 46 21 3 0
 
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab GU SXQOL 1 Y 0 Initial Registration 116 94 42 21 6 1
            116 94 42 21 6 1
 
      2 Y 1 Chemo + RT 53 42 19 11 1 0
          2 Chemo + RT + Atezolizumab 52 45 20 9 4 0
            105 87 39 20 5 0
 
S1820-Rectal, Diet modification to manage GI sx PEOLC SXQOL 1 Y 0 Run-In 41 41 33 12 5 0
            41 41 33 12 5 0
 
      2 Y 1 Diet Modification Coaching 14 14 14 4 0 0
          2 Healthy Living Education 12 12 10 3 0 0
            26 26 24 7 0 0
 
S1823-GCT, Obs. Cohort, miRNA371 PREV   1 Y 1 Observation 32 32 32 30 14 5
            32 32 32 30 14 5
 
S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD LYMPH SXQOL 1 Y 1 Nivolumab + AVD 133 124 69 37 10 2
          2 Brentuximab Vedotin + AVD 134 121 71 39 13 2
            267 245 140 76 23 4
 
S1827-SCLC, MRI Surveillance +/- PCI LUNG SXQOL 1 Y 1 PCI + MRI brain surveillance 9 9 8 5 0 0
          2 MRI brain surveillance 10 10 9 3 0 0
            19 19 17 8 0 0
 
S1904-Breast, Decision making for chemoprevention PREV   1 Y   0 0 0 0 0 0
            0 0 0 0 0 0
 
A021502-Colon, Stg III, Chemo +/- Atezol, ATOMIC GI SXQOL 1 E   37 16 10 7 4 0
            37 16 10 7 4 0
 
A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) GU SXQOL 1 E   7 1 1 0 0 0
            7 1 1 0 0 0
 
A031704-RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo GU SXQOL 1 E   40 38 24 15 5 0
            40 38 24 15 5 0
 
      2 E   19 19 12 6 4 2
            19 19 12 6 4 2
 
A221602-CINV in HEC patients, Olanza +/- Fosapre SXQOL PREV 1 E   19 19 6 5 3 1
            19 19 6 5 3 1
 
      2 E   10 10 3 2 1 0
            10 10 3 2 1 0
 
EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T MELAN SXQOL 1 E   49 5 1 0 0 0
            49 5 1 0 0 0
 
      2 E   19 5 3 2 1 0
            19 5 3 2 1 0
 
EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER) GU SXQOL 0 E   137 58 29 11 4 1
            137 58 29 11 4 1
 
      1 E   125 54 27 11 6 0
            125 54 27 11 6 0
 
EA9161-CLL, untreated, IOV vs IO in younger pts LEUK SXQOL 0 E   89 71 37 18 8 2
            89 71 37 18 8 2
 
      1 E   135 71 36 17 9 2
            135 71 36 17 9 2
 
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT BREAST SXQOL 1 E   2 1 0 0 0 0
            2 1 0 0 0 0
 
      2 E   2 1 0 0 0 0
            2 1 0 0 0 0
 
NRGBR004-BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo BREAST SXQOL 1 E   6 5 3 2 1 0
            6 5 3 2 1 0
 
      2 E   3 2 1 1 0 0
            3 2 1 1 0 0
 
NRGCC003-SCLC, PCI or HA-PCI LUNG SXQOL 1 E   4 0 0 0 0 0
            4 0 0 0 0 0
 
      2 E   4 0 0 0 0 0
            4 0 0 0 0 0
 
NRGGU005-PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT GU SXQOL 1 E   5 4 4 3 2 0
            5 4 4 3 2 0
 
NRGLU002-LUNG, Limited Met NSCLC, MST vs LCT + MST LUNG SXQOL 1 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
A011401-Breast, adj, Stage II/III HER2-, weight loss BREAST SXQOL 1 E   320 41 17 8 3 1
            320 41 17 8 3 1
 
      2 E   298 38 16 8 3 1
            298 38 16 8 3 1
 
      3 E   1 1 1 1 1 1
            1 1 1 1 1 1
 
A011502-Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo BREAST PREV 1 E   202 62 39 22 8 3
            202 62 39 22 8 3
 
A021602-PANC, Adv PNET Blinded Cabozantinib v Placebo GI SXQOL 1 E   10 5 3 2 2 0
            10 5 3 2 2 0
 
A021806-Pancreas, Perioperative vs Adjuvant Chemo GI SXQOL 0 E   1 1 1 1 0 0
            1 1 1 1 0 0
 
      1 E   1 1 1 1 0 0
            1 1 1 1 0 0
 
A031501-Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs GU SXQOL 0 E   88 31 22 9 3 1
            88 31 22 9 3 1
 
      1 E   80 25 18 6 2 0
            80 25 18 6 2 0
 
A031801-GU, mRCC, Cabozantinib +/- Radium-223 GU SXQOL 1 E   1 1 1 1 1 0
            1 1 1 1 1 0
 
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO LUNG SXQOL 1 E   4 4 4 4 1 0
            4 4 4 4 1 0
 
A211102-Breast, Atypia via RPFNA, Metformin v Placebo PREV   0 E   6 0 0 0 0 0
            6 0 0 0 0 0
 
      1 E   3 0 0 0 0 0
            3 0 0 0 0 0
 
      2 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
A211601-Breast, Stg II-III, Aspirin PREV   1 E   2 0 0 0 0 0
            2 0 0 0 0 0
 
A221405-Breast, ET interruption, Pregnancy Outcomes SURV   1 E   20 0 0 0 0 0
            20 0 0 0 0 0
 
A221505-Brst, Hypofractionated Post Mast Rad SXQOL   1 E   20 6 3 0 0 0
            20 6 3 0 0 0
 
A221702-BREAST, SLN/ALND +/- ARM SXQOL   1 E   15 15 0 0 0 0
            15 15 0 0 0 0
 
A221805-Colorectal, Duloxetine for Oxaliplatin CIPN SXQOL   1 E   1 1 1 1 0 0
            1 1 1 1 0 0
 
A231602C-Blood Cancer, Assess Financial Difficulty CCD   1 E   4 4 4 0 0 0
            4 4 4 0 0 0
 
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo OTHER SXQOL 1 E   1 1 0 0 0 0
            1 1 0 0 0 0
 
B51-Breast, Regional Nodal XRT BREAST SXQOL 1 E   47 8 5 2 1 0
            47 8 5 2 1 0
 
EA2186-PANC, mets, Gem+Abraxane vs 5-FU+LV+Nal-IRI GI SXQOL 1 E   2 2 2 2 2 0
            2 2 2 2 2 0
 
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL 1 E   6 2 0 0 0 0
            6 2 0 0 0 0
 
EA9131-Leuk, Strategy to decrease early APL deaths SURV   1 E   51 16 12 7 2 0
            51 16 12 7 2 0
 
EAA173-MYEL, SMM, Rd +/- Daratumumab MMYEL SXQOL 0 E   21 21 12 4 3 0
            21 21 12 4 3 0
 
      1 E   9 9 4 1 0 0
            9 9 4 1 0 0
 
EAQ171CD-Smoke Free Support Study 2.0 CCD   0 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
      1 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
EAZ171-Breast, Stg I-III, TIPN Docetaxel/Paclitaxel SXQOL   1 E   1 1 1 0 0 0
            1 1 1 0 0 0
 
G0263-Cerv, Stg I/IIA, adjv RT vs chemoRT OTHER SXQOL 1 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
NHLBIMDS-LEUK, National MDS Study CCD   1 E   94 31 18 13 7 1
            94 31 18 13 7 1
 
NRGBN003-Mening, Grd II, Observation vs Irradiation OTHER SXQOL 1 E   5 2 0 0 0 0
            5 2 0 0 0 0
 
      2 E   3 2 0 0 0 0
            3 2 0 0 0 0
 
NRGCC007-CCD, Increased Dose of SCP in Pros Survivors CCD   0 E   2 2 2 2 1 0
            2 2 2 2 1 0
 
      1 E   2 2 2 2 1 0
            2 2 2 2 1 0
 
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide GU SXQOL 1 E   1 1 1 1 0 0
            1 1 1 1 0 0
 
NRGGY005-OVAR, Cedir vs Olaparib vs C+O vs Std of Care OTHER SXQOL 1 E   4 0 0 0 0 0
            4 0 0 0 0 0
 
NRGHN001-Nasopharyngeal , Indiviual Tx EBV OTHER SXQOL 1 E   9 0 0 0 0 0
            9 0 0 0 0 0
 
      2 E   8 0 0 0 0 0
            8 0 0 0 0 0
 
      3 E   7 0 0 0 0 0
            7 0 0 0 0 0
 
NRGHN004-HN, Adv, RT+Durvalumab vs RT+Cetuximab OTHER SXQOL 1 E   6 4 4 2 1 0
            6 4 4 2 1 0
 
      2 E   6 4 4 2 1 0
            6 4 4 2 1 0
 
NRGHN005-HN, early stg P16-pos, randomize de-intensifi OTHER SXQOL 1 E   3 3 0 0 0 0
            3 3 0 0 0 0
 
NRGLU005-LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo LUNG SXQOL 1 E   1 0 0 0 0 0
            1 0 0 0 0 0
 
R0724-Cervical, Chem+RT +/- Adj. Chemo OTHER SXQOL 1 E   1 0 0 0 0 0
            1 0 0 0 0 0
 

03-DEC-2020 6:10

Cancer Coltrol Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Admin CCAdmin Registration/Phase Open Date
S1904 Breast, Decision making for chemoprevention PREV   1 Registration 01-Sep-20